Prognostic Role of MicroRNAs in Human Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Table 2

Main characteristics of the studies included in the meta-analysis.

Study	Population	Study period	Sample number (patient/control)	Source of miRNA	miRNA expressed	Cancer type/subtype	Histological stage	miRNA analysis platform	Follow-up
Chen et al., 2017 [22]	China	Jul 2004–Jun 2009	165/165	Tissue (FFPE)	miR-148a	SCC: 45.5%; AC: 54.5%	T1 = 34; T2 = 89; T3 = 41; U = 1	ISH	5 yrs
Liu et al., 2017 [52]	China	2003–2005	87	Tissue (FFPE)	miR-29c	AC	T1 = 10; T2 = 62; T3 = 15	miRNA array/qRT-PCR	5 yrs
Chen et al., 2016 [23]	China	Jan 2010–Jun 2012	134	Tissue (FFPE)	miR-200a	SCC: 41.8%; AC: 48.5%; ASC: 5.2%; LCC: 4.5%	T1 = 34; T2: 26; T3a: 74	ISH	28 months (1–58)
Wang et al., 2016 [34]	China	Jan 2014–May 2015	39/39	Tissue	miR-148b	SCC: 38.5%; AC: 61.5%	T1 = 12; T2, T3 & T4 = 27	qRT-PCR	(2–60) months
Shang et al., 2016 [53]	China	Jun 2009–Sept 2010	139/139	Tissue	miR-383	SCC: 59%; AC: 41%	T1 & T2 = 63; T3 = 76	qRT-PCR	60 months
Chen et al., 2015 [50]	China	Mar 2007–Apr 2013	137/137	Tissue	miR-153	SCC: 49.6%; AC: 50.4%	T1 & T2 = 104; T3 & T4 = 33	qRT-PCR	5 yrs
Ge et al., 2015 [35]	China	May 2007–Apr 2012	151/151	Tissue	miR-148b	SCC: 46.4%; AC: 43.7%	T1 & T2 = 91; T3 & T4 = 60	qRT-PCR	N/A
Skrzypski et al., 2014 [30]	Poland	2001–2012	134	Tissue	miR-662/miR-192/miR-192	SCC	T1a = 29; T1b = 65; T2a = 4 & T2b = 31 & T3a = 5	miRNA array/qRT-PCR	5.8 yrs (4.1–10.0)
Yu et al., 2014 [13]	China	May 2008–Jul 2010	164/164	Serum	miR-375	SCC: 26.8%, AC: 60.98%, Others: 12.2%	T1 = 3; T2 = 42; T3 = 58; T4 = 34	qRT-PCR	24 months (0–56)
			53/53	Serum	miR-375	N/A	N/A	qRT-PCR	24 months (0–56)
Xiao-chun et al., 2013 [19]	China	2001–2007	60/60	Tissue	miR-21	NSCLC	T1 & T2 = 29; T3 & T4 = 31	qRT-PCR	N/A
Sanfiorenzo et al., 2013 [17]	France	Mar 2008–Mar 2010	52/20	Plasma	miR-155	SCC: 48%; AC: 52%	T1a = 8; T1b = 14; T2a = 5; T2b = 8; T3a = 7	qRT-PCR	N/A
Chen et al., 2013 [33]	China	Feb 2008–Dec 2009	47	Tissue (FFPE)	miR-148a	SCC: 52.1%; AC: 47.9%	T1 = 25; T2 & T3 = 23	qRT-PCR	N/A
Jang et al., 2012 [14]	USA	Jan 1997–Sep 2008	56/56	Tissue (FF)	miR-708	AC	N/A	miRNA array/qRT-PCR	N/A
			47/47	Tissue (FFPE)	miR-708	AC	N/A	miRNA array/qRT-PCR	N/A
Liu et al., 2012 [24]	China	2003–2005	70/70	Tissue	miR-21	AC	T1 = 10; T2 = 62; T3 = 15	miRNA array/qRT-PCR	2 yrs
Li et al., 2012 [51]	China	Jan 2006–Dec 2007	96/96	Tissue	miR-375	SCC: 43.75%; AC: 56.25%	T1 or T2 = 66; T3 = 30	qRT-PCR	30 months (8–69)
Tan et al., 2011 [31]	China	2000–2002	60/60	Tissue	miR-31	NSCLC	T1 = 21; T2 = 17 & T3 = 22	miRNA array/qRT-PCR	N/A
Donnem et al., 2011 [15]	Norway	1990–2004	191	Tissue (SCC)	miR-155	SCC	N/A	ISH	86 months (48–216)
			95	Tissue (AC)	miR-155	AC	N/A	ISH	86 months (48–216)
Saito et al., 2011 [16]	USA	1987–2009	89/89	Tissue	miR-21/miR-155	AC	T1 = 57; t2 = 22; T3 = 10	qRT-PCR	5 yrs
	Norway	1988–2003	37/37	Tissue	miR-21/miR-155	AC	T1 = 21; T2 = 5; T3 = 11	qRT-PCR	5 yrs
	Japan	1998–2008	191/191	Tissue	miR-21/miR-155	AC	T1 = 142; T2 = 49	qRT-PCR	5 yrs
Wang et al., 2011 [18]	China	2003–2005	88/17	Serum	miR-21	SCC: 23.9%, AC: 42%, Others: 34.1%	T1, T2 = 47; T3 = 41	miRNA array/qRT-PCR	52.16 months (1–73)
Gao et al., 2011 [25]	China	Feb 2004–Jan 2005	30/30	Tissue	miR-21	SCC	T1 = 17; T2 = 12 & T3 = 13	miRNA array/qRT-PCR	4-5 yrs
Gao et al., 2010 [26]	China	Apr 2008–Sep 2008	47/47	Tissue	miR-21/miR-181a	SCC: 55.32%; AC: 44.68%	T1 = 22; T2 = 12 & T3 = 13	miRNA array/qRT-PCR	N/A
Voortman et al., 2010 [20]	USA	N/A	697/79	Tissue	miR-155/miR-21/miR-let-7/miR-29b/miR-34a/b/c	NSCLC	N/A	qRT-PCR	8 yrs
Raponi et al., 2009 [28]	USA	Oct 1991–Jul 2002	61/10	Tissue	miR-155/mir-146b	SCC	T1: 33; T2–T4 = 28	qRT-PCR	3 yrs
Markou et al., 2008 [27]	Greece	2004–2005	48/48	Tissue	miR-21	SCC: 47.9%; AC: 52.1%	T1 & T2 = 32; T3 & T4 = 16	qRT-PCR	39 months
Yu et al., 2008 [21]	Taiwan	Sept 2000–Dec 2003	112	Tissue	miR-let-7	N/A	N/A	miRNA array/qRT-PCR	N/A
Yanaihara et al., 2006 [29]	USA	N/A	104/104	Tissue	miR-let-7/miR-155	SCC: 37.5%; AC: 62.5%	T1 = 65; T2 = 17; T3 & T4 = 22	qRT-PCR	N/A
Takamizawa et al., 2004 [32]	Japan	N/A	143	Tissue	miR-let-7	SCC: 17.5%; AC: 73.4%; LCC: 6.3%; ASC: 2.8%	T1 = 71; T2 = 19 & T3 = 49	qRT-PCR	N/A

FF: formalin-fixed; FFPE: formalin-fixed paraffin-embedded; AC: adenocarcinoma; SCC: squamous cell carcinoma; LCC: large-cell carcinoma; ASC: adeno-squamous carcinoma; NSCLC: non-small-cell lung carcinoma; qRT-PCR: quantitative real time PCR; N/A: not available.